SCHEMBL19668774

SCHEMBL19668774

CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)Oc4ccc(CC(P(=O)(O)O)P(=O)(O)O)cc4)CC3)cc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.61
▸ KMT2A Q03164 6/20 0.61
▸ TDP1 Q9NUW8 3/20 0.61
▸ ATM Q13315 1/20 0.61
▸ HSD17B10 Q99714 3/20 0.61
▸ PIK3CD O00329 1/20 0.60
▸ PIK3R1 P27986 1/20 0.60
▸ PIK3CA P42336 1/20 0.60
▸ PIK3CG P48736 1/20 0.60
▸ DRD3 P35462 1/20 0.59
▸ MEN1 O00255 5/20 0.58
▸ HTT P42858 4/20 0.58
▸ ALDH1A1 P00352 4/20 0.58
▸ LMNA P02545 3/20 0.58
▸ HPGD P15428 2/20 0.58
▸ TSHR P16473 2/20 0.58
▸ USP2 O75604 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ HIF1A Q16665 1/20 0.57
▸ BRD4 O60885 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19668802 0.94 KDM4E (0.66) KDM4EKMT2ATDP1ATMHSD17B10
SCHEMBL19668784 0.87 HSD17B10 (0.61) KDM4EKMT2AHSD17B10PIK3CDPIK3R1
SCHEMBL19668397 0.87 KDM4E (0.61) KDM4EKMT2ATDP1ATMHSD17B10
SCHEMBL19668798 0.87 KDM4E (0.61) KDM4EHSD17B10PIK3CDPIK3R1PIK3CA
SCHEMBL21074739 0.86 LMNA (0.60) KDM4EKMT2ATDP1ATMHSD17B10
SCHEMBL21074731 0.85 LMNA (0.57) KDM4EKMT2ATDP1ATMHSD17B10
SCHEMBL19668786 0.85 DRD3 (0.59) KDM4EKMT2AHSD17B10DRD3MEN1
SCHEMBL26931897 0.84 KDM4E (0.59) KDM4EHSD17B10PIK3CDPIK3R1PIK3CA
SCHEMBL26932072 0.84 LMNA (0.59) KDM4EKMT2ATDP1ATMHSD17B10
SCHEMBL21074647 0.84 HSD17B10 (0.69) KDM4EKMT2ATDP1HSD17B10PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624057-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2026-05-12 — — US disclosed
US-20240182504-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BIOVINC LLC (US) 2024-06-06 — — US disclosed
US-11840549-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2023-12-12 — — US disclosed
US-11840549-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2023-12-12 — — US disclosed
US-11840549-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2023-12-12 — — US disclosed
US-20210101920-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-04-08 — — US disclosed
US-20210101920-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-04-08 — — US disclosed
US-10865220-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2020-12-15 — — US disclosed
US-10865220-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2020-12-15 — — US disclosed
US-20190169214-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BIOVINC LLC (US) 2019-06-06 — — US disclosed
US-20190169214-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BIOVINC LLC (US) 2019-06-06 — — US disclosed
EP-3464307-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF Biovinc, LLC. (US) 2019-04-10 — — EP disclosed
WO-2017210611-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BIOVINC, LLC. (US) 2017-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865220-B2 Bisphosphonate quinolone conjugates and uses thereof BPGM, PHPT1, NQO2 KDM4E 3437/4885KMT2A 4250/4885TDP1 2255/4885
US-20190169214-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BPGM, PHPT1, NQO2 KDM4E 3437/4885KMT2A 4250/4885TDP1 2255/4885
US-20240182504-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BPGM, PHPT1, NQO2 KDM4E 3437/4885KMT2A 4250/4885TDP1 2255/4885
US-11840549-B2 Bisphosphonate quinolone conjugates and uses thereof BPGM, PHPT1, NQO2 KDM4E 3437/4885KMT2A 4250/4885TDP1 2255/4885
US-12624057-B2 Bisphosphonate quinolone conjugates and uses thereof PTMS, CYP24A1, PHPT1 KDM4E 476/4885KMT2A 2233/4885TDP1 3724/4885
US-20210101920-A1 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BPGM, PHPT1, NQO2 KDM4E 3437/4885KMT2A 4250/4885TDP1 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback